Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.

British Journal of Haematology
Brandon S ImberJoachim Yahalom

Abstract

Radiotherapy is potentially an important salvage strategy post-chimeric antigen receptor T cell therapy (CART), but limited data exist. We reviewed 14 patients treated with salvage radiation post-CART progression (SRT). Most received SRT for first post-CART relapse (71%) to sites previously PET-avid pre-CART (79%). Median overall survival (OS) post-SRT was 10 months. Post-SRT, six localized relapses achieved 100% response (3 = complete, 3 = partial), with improved freedom from subsequent relapse (P = 0·001) and OS (P = 0·004) compared to advanced stage relapses. Three were bridged to allogeneic transplantation; at analysis, all were alive/NED. SRT has diverse utility and can integrate with novel agents or transplantation to attempt durable remissions.

References

Mar 12, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradford S HoppeJoachim Yahalom
Aug 4, 2009·International Journal of Radiation Oncology, Biology, Physics·Tithi BiswasLouis S Constine
Apr 4, 2013·Cancer Discovery·Michel SadelainIsabelle Rivière
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Mar 11, 2015·Nature·Christina Twyman-Saint VictorAndy J Minn
May 20, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Veronika BachanovaUNKNOWN Center for International Blood and Marrow Transplant Research Lymphoma Working Committee
May 23, 2017·Translational Lung Cancer Research·James P FlynnSaumil J Gandhi
Dec 12, 2017·The New England Journal of Medicine·Sattva S NeelapuWilliam Y Go
Feb 1, 2018·The New England Journal of Medicine·Jae H ParkMichel Sadelain
Jul 13, 2018·Therapeutic Advances in Vaccines and Immunotherapy·Jamie Honeychurch, Timothy M Illidge
Sep 15, 2018·Best Practice & Research. Clinical Haematology·Ranjit Nair, Sattva S Neelapu
Nov 13, 2018·Molecular Therapy : the Journal of the American Society of Gene Therapy·Carl DeSelmMichel Sadelain
Dec 7, 2018·The New England Journal of Medicine·Stephen J SchusterUNKNOWN JULIET Investigators
Jun 9, 2019·International Journal of Radiation Oncology, Biology, Physics·Austin J SimTimothy J Robinson

❮ Previous
Next ❯

Citations

Mar 5, 2020·British Journal of Haematology·Rebecca Shakir, N George Mikhaeel
Jan 27, 2021·Nature Reviews. Clinical Oncology·Haneen ShalabiNirali N Shah
Apr 4, 2021·Journal of Personalized Medicine·Cristina FerrariGiuseppe Rubini
Jun 16, 2021·Clinical Lymphoma, Myeloma & Leukemia·Christopher M WrightIma Paydar
Aug 11, 2021·The British Journal of Radiology·Carl DeSelm
Aug 12, 2021·The British Journal of Radiology·Eric D BrooksChelsea C Pinnix
Jul 10, 2021·International Journal of Radiation Oncology, Biology, Physics·Nicholas B FiguraMichael D Jain

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.